Brief: Karyopharm Therapeutics Q4 Net Income USD -41.837 Million
29/02/2024 12:30
Feb 29 (Reuters) - Karyopharm Therapeutics Q4 operating expenses USD 71.555 million. * Q4 operating income USD -37.808 million * outlook FY revenue USD 140-160 million
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview